bioAffinity to present CyPath Lung test at North Carolina event

Key Highlights

• bioAffinity Technologies will participate in North Carolina’s “Battle of the Blues” event on Nov. 5, 2026.
• The company plans to discuss its CyPathae Lung test for assessing cancer risk in pulmonary nodules.
• bioAffinity cited prior study and case-study results, while noting CyPath Lung is not a standalone diagnostic.

bioAffinity Technologies Inc. (Nasdaq: BIAF; BIAFW) said it will join physicians, patients and other healthcare providers at the Lung Cancer Initiative of North Carolina’s “Battle of the Blues” event on November 5, 2026, during National Lung Cancer Awareness Month. The company said the event will highlight advancements in diagnostics and therapies for lung cancer, including presentations of major clinical trial results intended to change physician practice and “actionable thoracic oncology results” for providers. This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice. bioAffinity plans to share information about CyPath Lung, which it describes as a noninvasive, patent-protected assay that analyzes the lung microenvironment using flow cytometry, artificial intelligence-driven analysis, and biomarkers. The test is designed to provide a binary result of “Likely” or “Unlikely” for malignancy to help physicians assess lung cancer risk in patients with pulmonary nodules and guide follow-up decisions. “During National Lung Cancer Awareness Month, it is important to highlight the fact that lung cancer diagnosis and treatment is advancing at a rapid pace. We are honored to be joining patient advocates and the dedicated physicians who play a crucial part in these advancements,” Maria Zannes, president and chief executive officer of bioAffinity Technologies, said. The release also described CyPath Lung as being marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. It said LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services. As support for the tests performance, bioAffinity pointed to a published clinical trial in high-risk patients that it said showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in detecting lung cancer in patients with indeterminate lung nodules smaller than 20 millimeters. The company also cited multiple case studies in which it said CyPath Lung detected lung cancer as early as Stage 1A. The company emphasized that CyPath Lung is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings and a patients overall clinical evaluation.

The original press release is available on stockhouse.com